Scott’s Liquid Gold-Inc. Reports Third Quarter Results

Scott’s Liquid Gold-Inc. Reports Third Quarter Results

Third Quarter 2020 Highlights:

  • Net sales of $7.2 million, negatively impacted by COVID-related supply chain issues, partially offset by Biz and Dryel acquisition
  • Net loss of $0.5 million (($0.04) per share)
    • Includes $0.3 million of expenses related to supply chain transition and Biz and Dryel acquisition
  • Gross margin of 44.8%, an increase of 3.8% from Q3 2019

DENVER–(BUSINESS WIRE)–
Scott’s Liquid Gold-Inc. (OTC: SLGD) today announced operating results for the three months ended September 30, 2020.

President and Chief Executive Officer Mark Goldstein stated, “As we previously announced, pandemic driven raw material and container shortages impacted our third quarter revenue. We have seen limited improvements throughout our supply chain and expect better results in the fourth quarter, though challenges remain.”

Net Sales

Net sales remained level for three months ended September 30, 2020 compared to last year because a decrease in sales due to COVID-driven supply chain shortages was offset by an increase in net sales due to our Kids N Pets, Biz and Dryel acquisitions.

Net sales for the nine months ended September 30, 2020 increased $0.8 million compared to last year due to our Kids N Pets, Biz and Dryel acquisitions, partially offset by decreased sales for multiple product lines due to COVID-related shortages.

Net Loss

Our net loss of $0.5 million for the three months ended September 30, 2020 was primarily driven by COVID-related supply chain issues, increased SG&A expenses attributable to supply chain transition, acquisition-related expenses and interest expense associated with our new debt. These were partially offset by an increase in gross profit driven by the introduction of our Kids N Pets and SLG One products during the fourth quarter of 2019, the introduction of our Biz and Dryel products during the third quarter of 2020, and margin increases associated with outsourcing.

We reported a $0.4 million decrease in net loss for the nine months ended 2020 compared to last year due to our Kids N Pets, Biz and Dryel acquisitions, improved margins due to outsourcing our manufacturing, and a $0.4 million transition payment received related to the termination of our MJ distribution agreement. These decreases in net loss were partially offset by decreased sales caused by COVID-related reduced store traffic and raw material supply chain issues, increased SG&A due to supply chain transition and acquisition-related expenses, gain on sale of equipment during 2019, and interest expense associated with our new debt.

Cash Flow

Cash flow provided by operating activities was $4.3 million for the nine months ended September 30, 2020, as compared to cash flow provided from operating activities of $1.1 million for the same 2019 period. The $3.2 million increase in operating cash flow was primarily the result of our Kids N Pets, Biz, and Dryel acquisitions, as well as our improved margins driven by cost savings from outsourcing.

About Scott’s Liquid Gold-Inc.

Scott’s Liquid Gold-Inc. develops, markets, and sells high-quality, high-value household and personal care products nationally and internationally to mass merchandisers, drugstores, supermarkets, hardware stores, e-commerce retailers, other retail outlets, and to wholesale distributors. Over the last 65+ years we have developed a reputation for delivering products that consumers know and trust.

Our flagship product, Scott’s Liquid Gold® Wood Care, is a leader in its category and is known for bringing life back to and protecting all types of natural wood surfaces. Our Kids N Pets® brands are award winning, safe, nontoxic, stain and odor removing products targeted toward households with children and pets. Our newly acquired Biz and Dryel are top performing laundry care products, with Biz being a top stain removing laundry additive, and Dryel being the market leader in at-home dry cleaning.

Scott’s Liquid Gold-Inc. also owns Neoteric Cosmetics, a personal care company with a rich history of offering products that deliver high-quality, proven results that customers expect. Neoteric’s personal care products are embraced and respected by both medical professionals and consumers alike and include brands such as Alpha® Skin Care, Prell®, and Denorex®. Neoteric Cosmetics is also the proud American specialty channel distributor for Batiste Dry Shampoo.

SCOTT’S LIQUID GOLD-INC. & SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Net sales

$

7,197

 

 

$

7,178

 

 

$

21,134

 

 

$

20,365

 

Cost of sales

 

3,973

 

 

 

4,235

 

 

 

11,578

 

 

 

12,877

 

Gross Profit

 

3,224

 

 

 

2,943

 

 

 

9,556

 

 

 

7,488

 

Gross Margin

 

44.8

%

 

 

41.0

%

 

 

45.2

%

 

 

36.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Advertising

 

169

 

 

 

105

 

 

 

531

 

 

 

491

 

Selling

 

2,168

 

 

 

1,369

 

 

 

5,371

 

 

 

4,381

 

General and administrative

 

1,377

 

 

 

1,223

 

 

 

4,284

 

 

 

3,604

 

Total operating expenses

 

3,714

 

 

 

2,697

 

 

 

10,186

 

 

 

8,476

 

(Loss) income from operations

 

(490

)

 

 

246

 

 

 

(630

)

 

 

(988

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

 

 

28

 

 

 

3

 

 

 

89

 

Interest expense

 

(137

)

 

 

(5

)

 

 

(215

)

 

 

(14

)

Gain on sale of equipment

 

 

 

 

 

 

 

 

 

 

 

110

 

Other income

 

 

 

 

 

 

 

350

 

 

 

 

(Loss) income before income taxes

 

(627

)

 

 

269

 

 

 

(492

)

 

 

(803

)

Income tax benefit

 

110

 

 

 

118

 

 

 

174

 

 

 

144

 

Net (loss) income

$

(517

)

 

$

387

 

 

$

(318

)

 

$

(659

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per common share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

$

(0.04

)

 

$

0.03

 

 

$

(0.03

)

 

$

(0.05

)

Diluted

$

(0.04

)

 

$

0.03

 

 

$

(0.03

)

 

$

(0.05

)

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

12,480

 

 

 

12,462

 

 

 

12,468

 

 

 

12,435

 

Diluted

 

12,480

 

 

 

12,462

 

 

 

12,468

 

 

 

12,435

 

SCOTT’S LIQUID GOLD-INC. & SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except par value amounts)

 

September 30,

 

 

December 31,

 

 

2020

 

 

2019

 

 

(Unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

$

174

 

 

$

1,094

 

Accounts receivable, net

 

4,451

 

 

 

2,695

 

Inventories, net

 

5,747

 

 

 

7,841

 

Income taxes receivable

 

107

 

 

 

705

 

Property and equipment held for sale

 

 

 

 

500

 

Prepaid expenses

 

701

 

 

 

368

 

Other current assets

 

 

 

 

71

 

Total current assets

 

11,180

 

 

 

13,274

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

129

 

 

 

124

 

Deferred tax asset

 

692

 

 

 

556

 

Goodwill

 

5,280

 

 

 

3,230

 

Intangible assets, net

 

15,105

 

 

 

8,719

 

Operating lease right-of-use assets

 

3,048

 

 

 

188

 

Other assets

 

38

 

 

 

 

Total assets

$

35,472

 

 

$

26,091

 

 

 

 

 

 

 

 

 

Liabilities and Shareholders’ Equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

$

2,959

 

 

$

1,809

 

Accrued expenses

 

589

 

 

 

422

 

Current portion of long-term debt

 

1,000

 

 

 

 

Operating lease liabilities, current portion

 

301

 

 

 

197

 

Total current liabilities

 

4,849

 

 

 

2,428

 

 

 

 

 

 

 

 

 

Long-term debt, net of current portion and debt issuance costs

 

4,031

 

 

 

 

Operating lease liabilities, net of current

 

2,977

 

 

 

19

 

Other liabilities

 

143

 

 

 

27

 

Total liabilities

 

12,000

 

 

 

2,474

 

 

 

 

 

 

 

 

 

Shareholders’ equity:

 

 

 

 

 

 

 

Preferred stock, no par value, authorized 20,000 shares; no shares issued and outstanding

 

 

 

 

 

Common stock; $0.10 par value, authorized 50,000 shares; issued and outstanding 12,513 shares (2020) and 12,462 shares (2019)

 

1,251

 

 

 

1,246

 

Capital in excess of par

 

7,418

 

 

 

7,250

 

Retained earnings

 

14,803

 

 

 

15,121

 

Total shareholders’ equity

 

23,472

 

 

 

23,617

 

Total liabilities and shareholders’ equity

$

35,472

 

 

$

26,091

 

SCOTT’S LIQUID GOLD-INC. & SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

 

Nine Months Ended

 

 

September 30,

 

 

2020

 

 

2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

Net loss

$

(318

)

 

$

(659

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

976

 

 

 

552

 

Stock-based compensation

 

106

 

 

 

119

 

Deferred income taxes

 

(136

)

 

 

(150

)

Gain on sale of equipment

 

 

 

 

(110

)

Change in operating assets and liabilities, net of effects of acquisition:

 

 

 

 

 

 

 

Accounts receivable

 

(1,756

)

 

 

336

 

Inventories

 

3,373

 

 

 

787

 

Prepaid expenses and other assets

 

(200

)

 

 

196

 

Income taxes receivable

 

598

 

 

 

1

 

Accounts payable, accrued expenses, and other liabilities

 

1,659

 

 

 

40

 

Total adjustments to net loss

 

4,620

 

 

 

1,771

 

Net cash provided by operating activities

 

4,302

 

 

 

1,112

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Acquisition

 

(10,529

)

 

 

 

Proceeds from sale of property and equipment

 

500

 

 

 

110

 

Purchase of internal-use software

 

 

 

 

(286

)

Purchase of property and equipment

 

(17

)

 

 

(101

)

Cash paid for leasehold improvements

 

(484

)

 

 

 

Reimbursement for leasehold improvements

 

247

 

 

 

 

Net cash used in investing activities

 

(10,283

)

 

 

(277

)

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Proceeds from revolving credit facility

 

6,525

 

 

 

 

Repayments of revolving credit facility

 

(3,795

)

 

 

 

Proceeds from term loan

 

3,000

 

 

 

 

Repayments of term loan

 

(167

)

 

 

 

Proceeds from PPP loan

 

600

 

 

 

 

Repayment of PPP loan

 

(600

)

 

 

 

Payments for debt issuance costs

 

(569

)

 

 

 

Proceeds from exercise of stock options

 

67

 

 

 

43

 

Net cash provided by financing activities

 

5,061

 

 

 

43

 

 

 

 

 

 

 

 

 

Net (decrease) increase in cash and cash equivalents

 

(920

)

 

 

878

 

 

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

1,094

 

 

 

6,232

 

Cash and cash equivalents, end of period

$

174

 

 

$

7,110

 

 

 

 

 

 

 

 

 

Supplemental disclosures:

 

 

 

 

 

 

 

Cash paid during the period for interest

$

23

 

 

$

14

 

Note Regarding Forward-Looking Statements

This news release may contain “forward-looking statements” within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” generally can be identified by the use of forward-looking terminology such as “assumptions,” “target,” “guidance,” “strategy,” “outlook,” “plans,” “projection,” “may,” “will,” “would,” “expect,” “intend,” “estimate,” “anticipate,” “believe”, “potential,” or “continue” (or the negative or other derivatives of each of these terms) or similar terminology.

Forward-looking statements convey our expectations, intentions, or forecasts about future events, circumstances, or results. All forward-looking statements, by their nature, are subject to assumptions, risks, and uncertainties, which may change over time and many of which are beyond our control. You should not rely on any forward-looking statement as a prediction or guarantee about the future. Actual future objectives, strategies, plans, prospects, performance, conditions, or results may differ materially from those set forth in any forward-looking statement. Some of the factors that may cause actual results or other future events or circumstances to differ from those in forward-looking statements are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Company’s subsequent Quarterly Reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statement made by us or on our behalf speaks only as of the date that it was made. We do not undertake to update any forward-looking statement to reflect the impact of events, circumstances, or results that arise after the date that the statement was made, except as required by applicable securities laws. You, however, should consult further disclosures (including disclosures of a forward-looking nature) that we may make in any subsequent filings with the Securities and Exchange Commission.

Investor Relations Contact:

Kevin Paprzycki, CFO

303.576.6032

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Home Goods Retail Specialty

MEDIA:

Logo
Logo

New SP+ Shuttle Operations Begin at Salt Lake City International Airport

CHICAGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — SP Plus Corporation (SP+), (Nasdaq: SP), a leading provider of technology-driven mobility solutions for aviation, commercial, hospitality and institutional clients throughout North America, today announced its commencement of shuttle bus operations at the newly-reconstructed Salt Lake City International Airport (SLC) in Utah.

SP+ hired more than 75 employees to effectively operate a new shuttle program at SLC, which includes 39 buses. The shuttle routes transport passengers around the airport’s premises, smoothly moving people to-and-from the airport terminals and the multi-gate hardstands where they board their airplanes.

In addition to the new shuttle program designed to serve travelers as they move through the air operations area, SP+ already provides comprehensive parking, shuttle and ground transportation management services for SLC.

“SP+ is excited to expand our role in working with the Salt Lake City Airport Authority by making the experience for passengers even easier and more enjoyable at this incredible new airport project,” added Jason Finch, Senior Vice President, West Airports at SP+.


SP+ 

facilitates the efficient movement of people, vehicles and personal belongings with the goal of enhancing the consumer experience while improving bottom line results for our clients. The Company provides professional parking management, ground transportation, remote baggage check-in and handling, facility maintenance, security, event logistics, and other technology-driven mobility solutions to aviation, commercial, hospitality, healthcare and government clients
across North America. For more
information
,
visit www.spplus.com.

CONTACT: Jill Nagel
  Senior Communications Manager
  [email protected], 312-274-2102

Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

— Cash and Cash Equivalents Totaled $52.9 Million as of September 30, 2020 —

BOSTON–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.

As previously reported, the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, change from baseline in the North Star Ambulatory Assessment, over one year of treatment compared to placebo. The secondary endpoint timed function tests also did not show statistically significant improvements. Edasalonexent was observed to be generally safe and well-tolerated in this trial, consistent with the safety profile seen to date. As previously announced, Catabasis is stopping activities related to the development of edasalonexent, including the ongoing GalaxyDMD open-label extension trial.

Catabasis has engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for the previously announced plan to explore and evaluate strategic options. Potential strategic options that may be evaluated include a merger, business combination, in-licensing, out-licensing or other strategic transaction. There can be no assurance that this process will result in any such transaction. We do not intend to discuss or disclose further developments during this process unless and until our Board of Directors has approved a specific action or otherwise determined that further disclosure is appropriate.

Third Quarter 2020 Financial Results

Cash Position: As of September 30, 2020, Catabasis had cash, cash equivalents and short-term investments of $52.9 million, compared to $53.9 million as of June 30, 2020. Based on the Company’s current operating plan, Catabasis expects that it has sufficient cash to fund operations for at least the next 12 months. Net cash used in operating activities for the three months ended September 30, 2020 was $10.0 million, compared to $6.5 million for the three months ended September 30, 2019.

R&D Expenses: Research and development expenses were $7.8 million for the three months ended September 30, 2020, compared to $4.7 million for the three months ended September 30, 2019.

G&A Expenses: General and administrative expenses were $3.1 million for the three months ended September 30, 2020, compared to $2.0 million for the three months ended September 30, 2019.

Operating Loss: Loss from operations was $10.9 million for the three months ended September 30, 2020, compared to $6.7 million for the three months ended September 30, 2019.

Net Loss: Net loss was $10.9 million, or $0.56 per share, for the three months ended September 30, 2020, compared to a net loss of $6.5 million, or $0.56 per share, for the three months ended September 30, 2019.

About Catabasis

Catabasis Pharmaceuticals is a biopharmaceutical company. Our mission is to bring hope with life-changing therapies to patients and families.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about its exploration and evaluation of strategic options, the termination of activities related to the edasalonexent program, including the ongoing GalaxyDMD open-label extension trial, and cash to fund operations, and other statements containing the words “believes,” “anticipates,” “plans,” “hopes,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of applicable securities laws and regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to: the impact of the COVID-19 pandemic and the effectiveness of the steps we have implemented to address the pandemic; the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; unexpected costs or expenses, including any that arise during the termination of activities related to the edasalonexent program; risks inherent in the Company’s exploration, evaluation and implementation of its review of strategic options; and general market and economic conditions; and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2020, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Catabasis Pharmaceuticals, Inc.

Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

2020

 

2019

 

2020

 

2019

 
Operating expenses:
Research and development

$

7,806

 

$

4,697

 

$

19,845

 

$

14,054

 

General and administrative

 

3,057

 

 

1,985

 

 

8,612

 

 

6,287

 

Total operating expenses

 

10,863

 

 

6,682

 

 

28,457

 

 

20,341

 

Loss from operations

 

(10,863

)

 

(6,682

)

 

(28,457

)

 

(20,341

)

Other income (expense):
Interest and investment income

 

4

 

 

214

 

 

231

 

 

697

 

Other expense, net

 

(3

)

 

(46

)

 

(96

)

 

(39

)

Total other income, net

 

1

 

 

168

 

 

135

 

 

658

 

Net loss

$

(10,862

)

$

(6,514

)

$

(28,322

)

$

(19,683

)

Net loss per share – basic and diluted

$

(0.56

)

$

(0.56

)

$

(1.59

)

$

(1.80

)

Weighted-average common shares outstanding used in net loss per share – basic and diluted

 

19,424,866

 

 

11,624,232

 

 

17,769,738

 

 

10,945,765

 

 

Catabasis Pharmaceuticals, Inc.

Selected Consolidated Balance Sheets Data

(In thousands)

(Unaudited)

 

September 30,

 

December 31,

2020

 

2019

Assets
Cash and cash equivalents

$

52,856

$

9,899

Short-term investments

 

 

 

26,345

 

Right-of-use asset

 

1,178

 

 

2,349

 

Other current and long-term assets

 

2,816

 

 

3,187

 

Total assets

 

56,850

 

 

41,780

 

Liabilities and stockholders’ equity
Current portion of operating lease liabilities

 

648

 

 

1,225

 

Long-term portion of operating lease liabilities

 

559

 

 

1,028

 

Other current and long-term liabilities

 

6,332

 

 

3,807

 

Total liabilities

 

7,539

 

 

6,060

 

Total stockholders’ equity

$

49,311

 

$

35,720

 

 

Catabasis Pharmaceuticals, Inc.

Selected Consolidated Statements of Cash Flows Data

(In thousands)

(Unaudited)

 

Nine Months Ended September 30,

2020

 

2019

Net cash used in operating activities

$

(24,424

)

$

(18,799

)

Net cash provided by (used) in investing activities

 

26,310

 

 

(578

)

Net cash provided by financing activities

 

40,829

 

 

21,848

 

Net increase in cash, cash equivalents and restricted cash

$

42,715

 

$

2,471

 

 

Investor relations:

Andrea Matthews

[email protected]

Media:

Elizabeth Higgins

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Clinical Trials

MEDIA:

Logo
Logo

Navient declares fourth quarter common stock dividend

WILMINGTON, Del., Nov. 12, 2020 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI), a leader in education loan management and business processing solutions, announced that its board of directors approved a 2020 fourth quarter dividend of $0.16 per share on the company’s common stock.

The fourth quarter 2020 dividend will be paid on December 18, 2020, to shareholders of record at the close of business on December 4, 2020.

About Navient

Navient (Nasdaq: NAVI) is a leading provider of education loan management and business processing solutions for education, healthcare, and government clients at the federal, state, and local levels. Navient helps clients and millions of Americans achieve success through technology-enabled financing, services, and support. Learn more at Navient.com.

Contact:

Media: Paul Hartwick, 302-283-4026, [email protected]

Investors: Nathan Rutledge, 703-984-6801, [email protected]

NAVICF

Berkeley Lights Reports Financial Results for Third Quarter of Fiscal Year 2020

EMERYVILLE, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today reported financial results for the quarter ended September 30, 2020.

Recent Highlights

  • Total revenue of $18.2 million for the third quarter, representing a 16% increase over the same period in 2019 and a 72% increase compared to the second quarter of 2020
  • Released Opto Cell Line Development 2.0 Workflow which enables higher throughput, assays for complex proteins such as multi-specifics, and acceleration of our customers’ path to production cell lines
  • Released new assays for Cell Therapy which drove more than a third of the quarter’s total platform placements

Third Quarter 2020 Financial Results

Revenue was $18.2 million for the quarter ended September 30, 2020, representing a 16% increase from the third quarter in the prior year. Product revenue was $14.1 million for the quarter, representing a 7% increase from the third quarter in the prior year. Service revenue was $4.1 million for the quarter, representing a 66% increase from the third quarter in the prior year.

Direct platform revenue was $12.4 million for the quarter, compared to $12.3 million for the third quarter in the prior year. Recurring revenue was $3.7 million for the quarter, compared to $1.9 million for the third quarter in the prior year. Milestone and related revenue was $2.1 million for the quarter, compared to $1.5 million for the third quarter in the prior year.

Gross profit was $12.8 million for the third quarter of 2020, up $1.1 million from $11.7 million for the corresponding prior year period. Gross margin was 70% for the third quarter of 2020, compared to 74% for the corresponding prior year period. 

Operating expenses were $21.0 million for the third quarter of 2020, compared to $15.9 million in the third quarter of the prior year, representing an increase of approximately 32%.

Net loss was $8.6 million in the third quarter of 2020, compared to $4.4 million in the same period in 2019.

Cash and cash equivalents were $237.2 million as of September 30, 2020 including $187.9 million of net proceeds from the Company’s IPO in mid-July.

Webcast and Conference Call Information

Berkeley Lights will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 12, 2020 at 1:30 PM Pacific Time/4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.berkeleylights.com. The webcast will be archived and available for replay for at least 90 days after the event.

About Berkeley Lights

Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.            

Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are: FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Forward Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. 

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Press Contact

[email protected]

Investor Contact

[email protected]

Berkeley Lights, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(In thousands, except share and per share data)

  Three months ended September 30,
  2020   2019
       
Revenue:      
Product revenue $ 14,103     $ 13,200  
Service revenue 4,105     2,467  
Total revenue 18,208     15,667  
Cost of sales:      
Product cost of sales 3,463     3,387  
Service cost of sales 1,937     610  
Total cost of sales 5,400     3,997  
Gross profit 12,808     11,670  
Operating expenses:      
Research and development 10,421     10,189  
General and administrative 7,229     3,136  
Sales and marketing 3,341     2,623  
Total operating expenses 20,991     15,948  
Loss from operations (8,183 )   (4,278 )
Other income (expense):      
Interest expense (361 )   (360 )
Interest income 51     221  
Other income (expense), net 10     (10 )
Loss before income taxes (8,483 )   (4,427 )
Provision for income taxes 118     21  
Net loss and net comprehensive loss $ (8,601 )   $ (4,448 )
       
Net loss attributable to common stockholders per share, basic and diluted $ (0.16 )   $ (1.78 )
Weighted-average shares used in calculating net loss per share, basic and diluted 53,596,982     2,943,162  
           

Berkeley Lights, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

Assets September 30,

2020
  December 31,

2019
  (unaudited)    
Current assets:      
Cash and cash equivalents $ 237,233     $ 81,033  
Trade accounts receivable 12,702     9,334  
Inventory 12,839     7,181  
Prepaid expenses and other current assets 8,682     7,799  
Total current assets 271,456     105,347  
Restricted cash 270     270  
Property and equipment, net 14,564     16,472  
Operating lease right-of-use assets 12,736     7,785  
Other assets 984     1,135  
Total assets $ 300,010     $ 131,009  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Trade accounts payable $ 4,178     $ 3,239  
Accrued expenses and other current liabilities 8,314     6,229  
Current portion of notes payable 6,595     5,765  
Deferred revenue 4,704     9,686  
Total current liabilities 23,791     24,919  
Notes payable, net of current portion 13,283     14,062  
Deferred revenue, net of current portion 1,168     1,461  
Lease liability, long-term 11,185     6,784  
Total liabilities 49,427     47,226  
Stockholders’ equity:      
Convertible preferred stock     224,769  
Common stock 3      
Additional paid-in capital 430,336     9,314  
Accumulated deficit (179,756 )   (150,300 )
Total stockholders’ equity 250,583     83,783  
Total liabilities and stockholders’ equity $ 300,010     $ 131,009  

Sun BioPharma, Inc. Provides Business Update and Reports Q3 2020 Financial Results

MINNEAPOLIS, Nov. 12, 2020 (GLOBE NEWSWIRE) — Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quarter ended September 30, 2020. Management is hosting an earnings call today at 4:30 p.m. ET.

The third quarter of 2020 was marked by meaningful corporate, financial and clinical progress.

Highlights

  • New CEO appointed on July 15, 2020
  • Fast Track designation received for SBP-101
  • Uplisted to Nasdaq Capital Market
  • Closed $10.5 Million Public Offering

“During the third quarter we strengthened our leadership team, bolstered the balance sheet and broadened our potential investor audience by uplisting to Nasdaq,” said Jennifer K. Simpson, PhD, MSN, CRNP President & Chief Executive Officer of Sun BioPharma. “These Q3 accomplishments lay the foundation to execute on near-term milestones. Those upcoming milestones include completing SBP-101’s enrollment in the current Phase 1b trial in Q4 2020, reporting data from our Phase 1 trial in 1H 2021, initiating a randomized Phase 2 study in 1H 2021 while evaluating additional opportunities for SBP-101. Looking ahead, we’re focused on rapidly advancing SBP-101’s clinical development to create significant shareholder value.”

Based on interim data from our Phase I trial, SBP-101 demonstrated a 54% objective response rate in combination with gemcitabine & abraxane (G&A); more than double historical standard of care for metastatic pancreatic cancer with G&A.

We believe SBP-101 has the potential to expand into other cancers with known elevated levels of polyamine metabolism.

Upcoming
Milestones

  • Completion of enrollment in the expansion cohort targeting (Q4’20)
  • Data from phase 1 trial (1H’21) 
  • Conference presentations (1H’21 or 2H’21)
  • Initiation of randomized phase 2 study (1H’21)


Third Quarter ended September 30, 2020 Financial Results

General and administrative expenses increased to $1.2 million in the third quarter of 2020, up from $0.6 million in the third quarter of 2019. The change in the third quarter is due primarily to increased employee compensation expense.

Research and development expenses increased to $0.8 million in the third quarter of 2020, up from $0.7 million in the third quarter of 2019. The change in the third quarter is due to increased spending on the company’s clinical study.

Operating expenses in the third quarter of 2020 were partially offset by a foreign currency exchange gain on the intercompany receivable balance; for the same quarter in 2019 other expense, net was primarily a foreign currency exchange loss.

Net loss in the third quarter of 2020 was $1.7 million, or $0.21 per diluted share, compared to a net loss of $1.4 million, or $0.23 per diluted share, in the third quarter of 2019.

Total cash was $10.9 million as of September 30, 2020. Total current assets were $11.4 million and current liabilities were $1.9 million as of the same date.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: November 12, 2020
Time: 4:30 PM Eastern Time
Toll Free: 877-407-9205
International: 201-689-8054

A replay of the call will be available from November 13, 2020 through November 26, 2020

Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 38324

The call will also be available over the Internet and accessible at: 
https://www.webcaster4.com/Webcast/Page/2556/38324  

About SBP-101 

SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for the exocrine pancreas and pancreatic ductal adenocarcinoma. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting complementary activity with an existing FDA-approved chemotherapy regimen. In clinical studies to date, SBP-101 has not shown exacerbation of the typical chemotherapy-related adverse events of bone marrow suppression and peripheral neuropathy. The safety data and PMI profile observed in Sun BioPharma’s current clinical trial provides support for continued evaluation of the compound in a randomized clinical trial. For more information, please visit https://clinicaltrials.gov/ct2/show/NCT03412799.

About Sun BioPharma 

Sun BioPharma Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Sun BioPharma Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101’s potential for efficacy in combination with other agents and in treating other types of cancer. SBP-101 was invented by Raymond J. Bergeron, PhD, a Distinguished Professor Emeritus at the University of Florida. Sun BioPharma has scientific collaborations with pancreatic disease experts at Cedars Sinai Medical Center in Los Angeles, the University of Rochester in New York, Scripps MD Anderson Cancer Center in San Diego, California, the University of Florida, the Austin Health Cancer Trials Centre in Melbourne, Australia, the Ashford Cancer Centre in Adelaide, Australia, the Blacktown Cancer and Haematology Centre in Sydney, Australia and the John Flynn Private Hospital in Tugun, Queensland, Australia. The company’s independent Data Safety Monitoring Board (DSMB) is Chaired by James Abbruzzese, MD, Professor of Medicine, and Chief, Division of Medical Oncology at Duke University School of Medicine. Professor David Goldstein, FRACP, Senior Staff Specialist at the Prince Henry & Prince of Wales Hospital / Cancer Care Centre in Sydney, Australia is Co-Chair of the DSMB. Further information can be found at: www.sunbiopharma.com. Sun BioPharma’s common stock is listed on The Nasdaq Stock Market LLC under the symbol SNBP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “believes,” “
dedicated,”
“expects,” “intends,” “may,”
“milestone,”
or “plans.” Examples of forward-looking statements include, among others, statements we make regarding, potential effects of FDA Fast Track designation, future determinations of the characteristics of SBP-101 and its effectiveness, uses of proceeds from recent financings. Forward-looking statements are neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially and adversely from the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) our ability to obtain additional funding to complete Phase 1 clinical trial; (ii) progress and success of our Phase 1 clinical trial; (iii) the impact of the current COVID-19 pandemic on our ability to complete enrollment in our current clinical trial; (iv) our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate (v) our ability to obtain regulatory approvals for our SBP-101 product candidate in the United States, the European Union or other international markets; (vi) the market acceptance and level of future sales of our SBP-101 product candidate; (vii) the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate; (viii) the rate of progress in establishing reimbursement arrangements with third-party payors; (ix) the effect of competing technological and market developments; (x) the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; and (xi) such other factors as discussed in Part I, Item 1A under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ from those anticipated in any such forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.

Contact Information:

Investors:

James Carbonara
Hayden IR
(646) 755-7412
[email protected]

Media:

Tammy Groene
Sun BioPharma, Inc.
(952) 479-1196
[email protected]

Sun
BioPharma, Inc

Consolidated Statements of Operations and Comprehensive Loss (unaudited)

(In thousands, except share and per share amounts)

                           
                           
    Three months ended September 30,   Nine months ended September 30,  
      2020       2019     Percent Change     2020       2019     Percent Change  
Operating expenses:                          
General and administrative   $ 1,223     $ 622     96.6 %   $ 2,348     $ 1,505     56.0 %  
Research and development     773       720     7.4 %     1,805       1,578     14.4 %  
Operating loss     (1,996 )     (1,342 )   48.7 %     (4,153 )     (3,083 )   34.7 %  
                           
Other income (expense):                          
Interest expense     (3 )     (3 )   0.0 %     (12 )     (2,187 )   -99.5 %  
Other income     239       (219 )   -209.1 %     55       (287 )   -119.2 %  
Total other income (expense)     236       (222 )   -206.3 %     43       (2,474 )   -101.7 %  
                           
Loss before income tax benefit     (1,760 )     (1,564 )   12.5 %     (4,110 )     (5,557 )   -26.0 %  
                           
Income tax benefit     89       190     -53.2 %     222       331     -32.9 %  
                           
Net loss     (1,671 )     (1,374 )   21.6 %     (3,888 )     (5,226 )   -25.6 %  
Foreign currency translation adjustment (loss)     (246 )     202     -221.8 %     (164 )     219     -174.9 %  
Comprehensive Loss   $ (1,917 )   $ (1,172 )   63.6 %   $ (4,052 )   $ (5,007 )   -19.1 %  
                           
Basic and diluted net loss per share $ (0.21 )   $ (0.23 )   -8.7 %   $ (0.55 )   $ (0.97 )   -43.3 %  
Weighted average shares outstanding – basic and diluted     7,888,609       6,009,904     31.3 %     7,085,326       5,385,986     31.6 %  
                           

 

Sun BioPharma, Inc.

Consolidated Balance Sheets (unaudited)

(In thousands, except share amounts)

         
         
         
         
         
    September 30, 2020   December 31, 2019
ASSETS   (Unaudited)    
Current assets:        
Cash   $ 10,870     $ 2,449  
Prepaid expenses and other current assets     335       283  
Income tax receivable     228       361  
Total current assets     11,433       3,093  
Other noncurrent assets     52       51  
Total assets   $ 11,485     $ 3,144  
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
Current liabilities:        
Accounts payable   $ 422     $ 597  
Accrued expenses     632       304  
Term debt     37       116  
Payroll protection plan loan     103        
Unsecured promissory note payable     742       742  
Total current liabilities     1,936       1,759  
         
Stockholders’ equity:        
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of September 30, 2020 and December 31 2019            
Common stock, $0.001 par value; 100,000,000 authorized; 9,649,427 and 6,631,308 shares issued and outstanding as of September 30, 2020 and December 31, 2019 respectively     10       7  
Additional paid-in capital     54,544       42,331  
Accumulated deficit     (45,146 )     (41,258 )
Accumulated comprehensive income     141       305  
Total stockholders’ equity     9,549       1,385  
Total liabilities and stockholders’ equity   $ 11,485     $ 3,144  
         

Sun BioPharma, Inc.

Consolidated Statements of Cash Flows (unaudited)

(In thousands)

             
             
             
             
             
    Nine Months Ended September 30    
     2020     2019     
Cash flows from operating activities:            
Net loss   $ (3,888 )   $ (5,226 )    
Adjustments to reconcile net loss to net cash used in operating activities:            
Stock-based compensation     969       958      
Amortization of debt discount           2,061      
Amortization of debt issuance costs           12      
Non-cash interest expense           102      
Changes in operating assets and liabilities:            
Income tax receivable     133       44      
Prepaid expenses and other current assets     64       (12 )    
Accounts payable     (347 )     179      
Accrued liabilities     328       15      
Net cash used in operating activities     (2,741 )     (1,867 )    
             
Cash flows from financing activities:            
Proceeds from sale of common stock and warrants net of offering costs of $2     1,746       3,142      
Proceeds from public offering of common stock and warrants net of underwriters discount and offering costs of $1,165     9,335            
Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7           810      
Proceeds from exercise of warrants     52            
Proceeds from payroll protection loan     103            
Repayment of demand note           (25 )    
Repayments of term debt     (81 )     (82 )    
Net cash provided by financing activities     11,155       3,845      
             
Effect of exchange rate changes on cash     7       (6 )    
             
Net change in cash     8,421       1,972      
Cash at beginning of period     2,449       1,405      
Cash at end of period   $ 10,870     $ 3,377      
             
Supplemental disclosure of cash flow information:            
Cash paid during period for interest   $ 5     $ 11      
             
Supplemental disclosure of non-cash transactions:            
Warrants issued for future services   $ 228     $      
Warrants issued to underwriter   $ 353     $      
Cashless exercise of warrants   $ 8     $      
Amortization of warrants as offering costs   $ 114     $      
Beneficial conversion feature on convertible notes   $     $ 353      
Warrants issued with convertible notes   $     $ 419      
Common stock converted into convertible notes payable   $     $ 25      
Conversion of convertible notes payable and accrued interest into common stock   $     $ 2,281      
Issuance of unsecured promissory note in exchange of vendor accounts payable   $     $ 742      
             

 

Ethan Allen Increases Quarterly Cash Dividend

DANBURY, CT, Nov. 12, 2020 (GLOBE NEWSWIRE) — Ethan Allen Interiors Inc. (“Ethan Allen” or “the Company”) (NYSE:ETH) announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.25 per share, payable on January 21, 2021 to shareholders of record at the close of business on January 7, 2021.

Farooq Kathwari, Chairman and CEO commented, “We are pleased that our Board made the decision to increase our regular quarterly dividend to $0.25, a 19% increase. These are unprecedent times. Our enterprise over the last 89 years has gone through the Great Depression, a World War, and several recessions including the Great Recession. We have come out stronger and more vibrant each time. We look forward to continuing our progress and remain cautiously optimistic.”

ABOUT ETHAN ALLEN

Ethan Allen Interiors Inc. (NYSE: ETH) is a leading interior design company, manufacturer and retailer in the home furnishings marketplace. Today the Company is a global luxury international home fashion brand that is vertically integrated from design through delivery, which affords its clientele a value proposition of style, quality and price. The Company provides complimentary interior design service to its clients and sells a full range of furniture products and decorative accents through a retail network of approximately 300 design centers in the United States and abroad as well as online at ethanallen.com. The design centers represent a mix of independent licensees and Company-owned and operated locations. The Company operates retail design centers located in the United States and Canada. The independently operated design centers are located in the United States, Asia, the Middle East and Europe. Ethan Allen owns and operates nine manufacturing facilities, including six manufacturing plants in the United States, two manufacturing plants in Mexico and one manufacturing plant in Honduras. Approximately 75% of its products are manufactured or assembled in these North American facilities.

For more information on Ethan Allen’s products and services, visit www.ethanallen.com.

Investor / Media Contact:  
Matt McNulty
Vice President, Finance
[email protected]

Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  • On track to report topline results from pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome in Q4 2020
  • Reported positive ELEKTRA results; Ovid and Takeda plan to initiate phase 3 registrational program of OV935/TAK935 (soticlestat) in Dravet Syndrome and Lennox-Gastaut syndrome after upcoming end-of-phase 2 meeting with FDA
  • Reported encouraging trial results from ARCADE open-label Phase 2 trial of soticlestat and ENDYMION long-term extension trial showing seizure frequency reductions over time in CDKL5 deficiency disorder and Dup15q syndrome and global improvements beyond motor seizure reduction in both CDKL5 deficiency disorder and Dup15q syndrome patients
  • In the ELEKTRA, ARCADE and ENDYMION trials, soticlestat appeared to be well-tolerated and demonstrated a safety profile consistent with the findings of previous studies with no new safety signals identified

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.

“We are very pleased with the progress made on our pipeline this quarter, which was highlighted by encouraging results from both the ELEKTRA and the ARCADE Phase 2 trials of OV935,” said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. “We look forward to advancing OV935 into a Phase 3 program for Dravet syndrome and Lennox-Gastaut syndrome next year after our end-of-phase 2 meeting with FDA. We are continuing to explore further clinical development opportunities in CDKL5 deficiency disorder, and Dup15q syndrome. Additionally, we remain on track to report topline data for the pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome this quarter. Pending a successful NEPTUNE readout, OV101 has the potential to become the first-ever treatment approved for Angelman syndrome, a disorder affecting some 500,000 patients worldwide.”

Pipeline Updates and Recent Highlights

OV101 (gaboxadol) for Angelman Syndrome

  • Hosted an investor seminar to review multiple aspects of Angelman syndrome, including its biological mechanism, and Ovid’s OV101 (gaboxadol) development program. The seminar featured external experts discussing the role of tonic inhibition, treatment practice in Angelman syndrome, measurement scales, and what to expect from the pivotal Phase 3 NEPTUNE trial of OV101 in Angelman syndrome. Topline results from NEPTUNE are expected in the fourth quarter of 2020. Results, if positive, are intended to support registrational filings for OV101 in the U.S. and the rest of the world.
  • Presented three abstracts from the OV101 Angelman syndrome clinical development program at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) 2020 Virtual Congress. The presentations included data on seizure and EEG outcomes from the Phase 2 STARS trial in individuals with Angelman syndrome; encore presentations of a study of caregiver insights in Angelman syndrome; and the utility of the Clinical Global Impression (CGI) scale for studying outcomes in neurodevelopmental conditions.

OV101 for Fragile X Syndrome

  • Presented an abstract from the OV101 Fragile X syndrome clinical development program at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) 2020 Virtual Congress. The presentation included additional data and analyses from the Phase 2 ROCKET clinical trial of OV101 in individuals with Fragile X syndrome.

OV935 (soticlestat) for Rare Developmental and Epileptic Encephalopathies (DEE)

  • Announced that the double-blind, randomized placebo-controlled, Phase 2 ELEKTRA trial of soticlestat met its primary endpoint in children with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

° Results showed a 27.8% median reduction from baseline in convulsive seizure (DS cohort) and drop seizure (LGS cohort) frequency compared to a 3.1% median increase in patients taking placebo during the 12-week maintenance period (median placebo-adjusted reduction=30.5%; p=0.0007, based on the efficacy analysis set of 120 patients with seizure data in the maintenance period).

° DS and LGS patients treated with soticlestat demonstrated a 29.8% median reduction in convulsive seizure (DS cohort) and drop seizure (LGS cohort) frequency compared to 0.0% change in median seizure frequency in patients taking placebo during the full 20-week treatment period (titration plus maintenance) of the ELEKTRA study (placebo-adjusted reduction=25.1%; p=0.0024).

° In the ELEKTRA DS cohort (n=51), patients treated with soticlestat demonstrated a 33.8% median reduction in convulsive seizure frequency compared to a 7.0% median increase in patients taking placebo during the full 20-week treatment period of the study (median placebo-adjusted reduction in seizure frequency is 46.0%; p=0.0007).

° In the ELEKTRA LGS cohort (n=88), patients treated with soticlestat demonstrated a 20.6% median reduction in drop seizure frequency compared to a 6.0.% median reduction in patients taking placebo during the full 20-week treatment period of the study (median placebo-adjusted reduction in seizure frequency is 14.8%; p=0.1279).

  • Ovid and Takeda plan to meet with regulatory authorities regarding initiating a Phase 3 registrational program of soticlestat in individuals with DS or LGS.
  • Reported results from the Phase 2 ARCADE and ENDYMION OLE trials of OV935 in patients with CDKL5 deficiency disorder (CDD) and Dup15q syndrome showing seizure frequency reduction over time.

° In CDD patients (n=12), median motor seizure frequency reduction was 24% during the 12-week maintenance period in the ARCADE study, increasing to a 50% reduction in the 9-month interval in the ENDYMION long-term extension study in the five CDD patients who reached nine months of continuous treatment.

° In Dup15q patients (n=8), there was an increase in median motor seizure frequency in the ARCADE study during the 12-week maintenance period; however, longer-term data from the four Dup15q patients who reached nine months of continuous treatment showed a 74% reduction in median motor seizure frequency in the 9-month interval.

° Global Improvements were reported in both patient populations as assessed by the Clinical Global Impression of Change (CGI-C; investigator) and Caregiver Global Impression of Change (Care GI-C) scales. 67% of CDD patients and 38% of Dup15q were deemed markedly improved with minimal or no adverse events on the CGI-C scale after starting soticlestat treatment. For the Care-GI-C scale, 92% of CDD caregivers reported improvement on soticlestat treatment at the end of the ARCADE study, with 41% reporting much and very much improved.

° The ARCADE study exit interviews from the caregiver also give insight into improvements in verbal and nonverbal communication, alertness/level of engagement, overall quality of daily functioning and caregiver-chosen domains to suggest benefits of soticlestat treatment in domains beyond seizure control.

  • OV935 was generally well tolerated in the ELEKTRA, ARCADE and ENDYMION studies and demonstrated a safety profile consistent with the findings of previous studies with no new safety signals identified. Data reported are consistent with, and build upon, previous findings with OV935.
  • To date, all patients who have completed the Phase 2 ARCADE and ELEKTRA trials have rolled over into the ENDYMION open-label extension study.

Third Quarter 2020 Financial Results

  • Revenue was $6.9 million for the third quarter ended September 30, 2020, as compared to zero for the same period in 2019. The increase was due to the receipt of the $20 million upfront payment under the collaboration and license agreement with Angelini Pharma Rare Diseases AG, of which $6.9 million was recognized in the third quarter as revenue and $13.1 million was deferred.
  • As of September 30, 2020, cash and cash equivalents totaled $86.9 million. The Company strengthened its financial position with the completion of a public offering in August 2020, resulting in net proceeds of approximately $46.7 million.
  • Research and development expenses were $15.9 million for the third quarter ended September 30, 2020, as compared to $11.6 million for the same period in 2019. The increase of $4.3 million was primarily due to an increase in preclinical and clinical activities related to Ovid’s ongoing development programs.
  • General and administrative expenses were $7.4 million for the third quarter ended September 30, 2020, as compared to $5.2 million for the same period in 2019. The increase of $2.2 million was primarily due to an increase in professional service fees, compliance and pre-commercialization expenses, payroll and payroll-related expenses offset by a decrease in general office expenses.
  • The Company reported a net loss of $16.4 million, or basic and diluted net loss per share attributable to common stockholders of $0.28, for the third quarter of 2020, as compared to a net loss of $16.6 million, or net loss per share attributable to common stockholders of $0.43, for the same period in 2019.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines in development. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). For more information on Ovid, please visit www.ovidrx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding: clinical and regulatory development of our programs, potential benefits of OV101, OV935 and our other research programs and the anticipated reporting schedule of clinical data and the potential benefits. You can identify forward-looking statements because they contain words such as “will,” “appears,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors”. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid’s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Condensed Consolidated Statements of Operations

(Unaudited)

    For the Three Months Ended September 30,   For the Three Months Ended September 30,   For the Nine  Months Ended September 30,   For the Nine  Months Ended September 30,
      2020       2019       2020       2019  
Revenue:                
License revenue   $ 6,914,034     $     $ 6,914,034     $  
Operating expenses:                
Research and development   $ 15,875,295     $ 11,597,633     $ 46,533,610     $ 30,052,432  
General and administrative     7,442,401       5,168,103       20,220,160       14,089,106  
Total operating expenses     23,317,696       16,765,736       66,753,770       44,141,538  
Loss from operations     (16,403,662 )     (16,765,736 )     (59,839,736 )     (44,141,538 )
Other (expense) income, net     (21,127 )     131,164       833,661       649,504  
Net loss   $ (16,424,789 )   $ (16,634,572 )   $ (59,006,075 )   $ (43,492,034 )
Net loss attributable to common stockholders   $ (16,424,789 )   $ (16,634,572 )   $ (59,006,075 )   $ (43,492,034 )
Net loss per share attributable to common stockholders, basic and diluted   $ (0.28 )   $ (0.43 )   $ (1.04 )   $ (1.21 )
Weighted-average common shares outstanding basic and diluted     59,406,215       38,504,825       56,586,640       35,872,441  





Selected Condensed Balance Sheet Data 


 (Unaudited)

    September 30,   December 31,
      2020     2019
         
Cash, cash equivalents and short-term investments   $ 86,866,275   $ 76,739,113
Working capital1     72,387,568     69,279,584
Total Assets     91,599,016     80,843,731
Total stockholder’s equity     63,643,038     70,023,561
             

1Working capital defined as current assets less current liabilities
           



Contacts

Investors and Media:
Ovid Therapeutics Inc.
Investor Relations & Public Relations
[email protected]

OR

Investors:

Argot Partners
Maeve Conneighton/Dawn Schottlandt
212-600-1902
[email protected]

Media:

Dan Budwick
1AB
[email protected]

BRP Group, Inc. Announces Third Quarter 2020 Results

–   Third Quarter 2020 Revenue Grew 72% Year-Over-Year to $65.8 Million   –

–   Third Quarter 2020 Organic Revenue Growth of 20%   –

–   “MGA of the Future” Policies in Force Cross 500,000 Policy Milestone   –

TAMPA, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) — BRP Group, Inc. (“BRP Group” or the “Company”) (NASDAQ: BRP), a rapidly growing independent insurance distribution firm delivering tailored insurance solutions, today announced its results for the third quarter ended September 30, 2020.

THIRD QUARTER 2020 AND SUBSEQUENT EVENT HIGHLIGHTS

  • Revenue increased 72% year-over-year to $65.8 million
  • Pro Forma Revenue(1) grew 70% year-over-year to $66.1 million
  • Organic Revenue Growth(2) was 20% year-over-year
  • “MGA of the Future” revenue grew 43% to $17.5 million, compared to $12.2 million in the prior-year period
  • GAAP net loss of $7.6 million and GAAP loss per share of $0.10
  • Adjusted Net Income(3) of $9.0 million, or $0.11(3) per fully diluted share
  • “MGA of the Future” policies in force grew by 54,313 to 500,301 at September 30, 2020 from 445,988 at June 30, 2020. Comparatively, in the third quarter 2019, policies in force grew sequentially by 41,179
  • Adjusted EBITDA(4) grew 48% to $10.9 million, compared to $7.4 million in the prior-year period
  • Pro Forma Adjusted EBITDA(5) of $11.0 million and Pro Forma Adjusted EBITDA Margin(5) of 17%
  • Closed two Partner acquisitions that generated total annualized revenue(6) of over $3 million for the 12-month period pre-acquisition; subsequent to September 30, 2020, announced an additional Partner acquisition that generated total annualized revenue(6) of $38.5 million for the 12-month period pre-acquisition

“BRP delivered another quarter of tremendous performance as we sustained high levels of organic and total growth, once again firmly validating our hybrid growth strategy and differentiated business model,” said Trevor Baldwin, Chief Executive Officer of BRP Group. “For the quarter, we generated year-over-year revenue growth of 72% to a record $65.8 million, highlighted by 20% organic revenue growth compared to the prior-year period, an impressive feat considering the ongoing challenges in the economic environment. Our ‘MGA of the Future’ platform also hit the 500,000 policy mark this quarter, which is an incredible milestone achieved in just four years’ time. With an amazing Colleague team executing for us every day, a robust Partnership pipeline and significant capacity on our balance sheet, we are poised to enter 2021 in the strongest position in our history.”

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2020, cash and cash equivalents were $50.2 million and there was $101.0 million of long-term debt outstanding. The Company had aggregate borrowing capacity of $400.0 million under its revolving credit facility.

On October 14, 2020, the Company entered into a new credit agreement with JPMorgan Chase Bank, N.A., to provide new senior secured credit facilities in an aggregate principal amount of $800.0 million. The amount consists of (i) a new term loan facility in the principal amount of $400.0 million maturing in 2027 and (ii) a new revolving credit facility with commitments in an aggregate principal amount of $400.0 million maturing in 2025. The Company used a portion of the proceeds from the new term loan facility to repay in full the Company’s obligations under its existing revolving credit facility and concurrently terminated the existing agreement.

NINE MONTHS 2020 RESULTS

  • Revenue increased 69% year-over-year to $171.3 million
  • Pro Forma Revenue(1) grew 74% year-over-year to $202.0 million
  • Organic Revenue Growth(2) of 15% year-over-year
  • “MGA of the Future” revenue(7) grew 41% to $41.6 million, compared to $29.5 million in the prior-year period
  • GAAP net loss of $10.8 million and GAAP loss per share of $0.22
  • Adjusted Net Income(3) of $27.5 million, or $0.39(3) per fully diluted share
  • Adjusted EBITDA(4) grew 47% to $33.3 million, compared to $22.7 million in the prior-year period
  • Pro Forma Adjusted EBITDA(5) of $47.6 million and Pro Forma Adjusted EBITDA Margin(5) of 24%
  • Closed 11 Partner acquisitions that generated total annualized revenue(6) of over $81.0 million for the 12-month period pre-acquisition

WEBCAST AND CONFERENCE CALL INFORMATION

BRP Group will host a webcast and conference call to discuss third quarter 2020 results today at 5:00 PM ET. A live webcast and a slide presentation of the conference call will be available on BRP Group’s investor relations website at ir.baldwinriskpartners.com. The dial-in number for the conference call is (877) 451-6152 (toll-free) or (201) 389-0879 (international). Please dial the number 10 minutes prior to the scheduled start time.

A webcast replay of the call will be available at ir.baldwinriskpartners.com for one year following the call.

ABOUT BRP GROUP, INC.

BRP Group, Inc. (NASDAQ: BRP) is a rapidly growing independent insurance distribution firm delivering tailored insurance and risk management insights and solutions that give our Clients the peace of mind to pursue their purpose, passion and dreams. We are innovating the industry by taking a holistic and tailored approach to risk management, insurance and employee benefits, and support our Clients, Colleagues, Insurance Company Partners and communities through the deployment of vanguard resources and capital to drive our growth. BRP represents over 500,000 Clients across the United States and internationally. For more information, please visit www.baldwinriskpartners.com.

FOOTNOTES

(1)   Pro Forma Revenue is a non-GAAP measure. Reconciliation of Pro Forma Revenue to commissions and fees, the most directly comparable GAAP financial measure, is set forth in the reconciliation table accompanying this release.

(2)   Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA Margin are non-GAAP measures. Reconciliation of Pro Forma Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, is set forth in the reconciliation table accompanying this release.

(3)   Annualized revenue represents the aggregate revenues of Partners acquired during the relevant period presented, for the most recent trailing twelve month period prior to acquisition by the Company, in each case, at the time the due diligence was concluded based on a quality of earnings review and not an audit.

(4)   Organic Revenue for the three and nine months ended September 30, 2019 used to calculate Organic Revenue Growth for the three and nine months ended September 30, 2020 was $38.4 million and $101.3 million, which is adjusted to reflect revenues from Partnerships that reached the twelve-month owned mark during the three and nine months ended September 30, 2020. Organic Revenue is a non-GAAP measure. Reconciliation of Organic Revenue to commissions and fees, the most directly comparable GAAP financial measure, is set forth in the reconciliation table accompanying this release.

(5)   Adjusted Net Income and Adjusted Diluted EPS are non-GAAP measures. Reconciliation of Adjusted Net Income to net income attributable to BRP Group, Inc. and reconciliation of Adjusted Diluted EPS to diluted loss per share, the most directly comparable GAAP financial measures, are set forth in the reconciliation table accompanying this release.

(6)   Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP measures. Reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, is set forth in the reconciliation table accompanying this release.

(7)   “MGA of the Future” was acquired by the Company on April 1, 2019 and, as a result, the revenue of “MGA of the Future” for a portion of the prior-year period is not included in the consolidated results of operations for the Company for such period and the 41% revenue growth rate for the nine months ended September 30, 2020 was calculated including periods during which “MGA of the Future” was not owned by the Company.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain various “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which represent BRP Group’s expectations or beliefs concerning future events. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or BRP Group’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements.

Factors that could cause actual results or performance to differ from the expectations expressed or implied in such forward-looking statements include, but are not limited to, those described under the caption “Risk Factors” in BRP Group’s Annual Report on Form 10-K for the year ended December 31, 2019, BRP Group’s Quarterly Report on Form 10-Q for the three months ended March 31, 2020 and BRP Group’s other filings with the SEC, which are available free of charge on the Securities and Exchange Commission’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to BRP Group or to persons acting on behalf of BRP Group are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and BRP Group does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

CONTACTS

INVESTOR RELATIONS

Investor Relations
(813) 259-8032
[email protected]

PRESS

Rachel Carr
Baldwin Risk Partners
(813) 418-5166
[email protected]

BRP GROUP, INC.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(Unaudited)

    For the Three Months

 Ended September 30,
  For the Nine Months

 Ended September 30,
(in thousands, except share and per share data)   2020   2019   2020   2019
Revenues:                
Commissions and fees   $ 65,843     $ 38,383     $ 171,270     $ 101,280  
                 
Operating expenses:                
Commissions, employee compensation and benefits   48,469     26,788     122,280     67,068  
Other operating expenses   12,146     6,320     30,577     16,711  
Amortization expense   5,185     3,082     13,231     6,793  
Change in fair value of contingent consideration   6,455     535     12,697     (3,222 )
Depreciation expense   258     184     663     460  
Total operating expenses   72,513     36,909     179,448     87,810  
                 
Operating income (loss)   (6,670 )   1,474     (8,178 )   13,470  
                 
Other expense:                
Interest expense, net   (922 )   (3,785 )   (2,554 )   (8,998 )
Other income (expense)   (23 )   5     (23 )   5  
Total other expense   (945 )   (3,780 )   (2,577 )   (8,993 )
                 
Income (loss) before income taxes   (7,615 )   (2,306 )   (10,755 )   4,477  
Income tax provision           12      
Net income (loss)   (7,615 )   (2,306 )   (10,767 )   4,477  
Less: net income (loss) attributable to noncontrolling interests   (4,347 )   (2,306 )   (5,379 )   4,477  
Net loss attributable to BRP Group, Inc.   $ (3,268 )   $     $ (5,388 )   $  
                 
Comprehensive income (loss)   $ (7,615 )   $ (2,306 )   $ (10,767 )   $ 4,477  
Comprehensive income (loss) attributable to noncontrolling interests   (4,347 )   (2,306 )   (5,379 )   4,477  
Comprehensive loss attributable to BRP Group, Inc.   (3,268 )       (5,388 )    
                 
Basic and diluted net loss per share   $ (0.10 )       $ (0.22 )    
Basic and diluted weighted-average shares of Class A common stock outstanding   33,098,356       24,371,304    

BRP GROUP, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share data)   September 30, 2020   December 31, 2019
Assets        
Current assets:        
Cash and cash equivalents   $ 50,220     $ 67,689  
Restricted cash   7,778     3,382  
Premiums, commissions and fees receivable, net   98,345     58,793  
Prepaid expenses and other current assets   2,689     3,019  
Due from related parties   41     43  
Total current assets   159,073     132,926  
Property and equipment, net   7,791     3,322  
Other assets   7,949     5,600  
Intangible assets, net   203,555     92,450  
Goodwill   344,396     164,470  
Total assets   $ 722,764     $ 398,768  
Liabilities, Mezzanine Equity and Stockholders Equity        
Current liabilities:        
Premiums payable to insurance companies   $ 83,617     $ 50,541  
Producer commissions payable   12,019     7,470  
Accrued expenses and other current liabilities   21,851     12,334  
Current portion of contingent earnout liabilities   7,065     2,480  
Total current liabilities   124,552     72,825  
Revolving lines of credit   101,000     40,363  
Contingent earnout liabilities, less current portion   78,323     46,289  
Other liabilities   2,194     2,017  
Total liabilities   306,069     161,494  
Commitments and contingencies        
Mezzanine equity:        
Redeemable noncontrolling interest   101     23  
Stockholders’ equity:        
Class A common stock, par value $0.01 per share, 300,000,000 shares authorized; 33,932,868 and 19,362,984 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively   339     194  
Class B common stock, par value $0.0001 per share, 50,000,000 shares authorized; 45,247,711 and 43,257,738 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively   4     4  
Additional paid-in capital   237,644     82,425  
Accumulated deficit   (14,038 )   (8,650 )
Notes receivable from stockholders   (519 )   (688 )
Total stockholders’ equity attributable to BRP Group, Inc.   223,430     73,285  
Noncontrolling interest   193,164     163,966  
Total stockholders’ equity   416,594     237,251  
Total liabilities, mezzanine equity and stockholders’ equity   $ 722,764     $ 398,768  

BRP GROUP, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

    For the Nine Months Ended September 30,
(in thousands)   2020   2019
Cash flows from operating activities:        
Net income (loss)   $ (10,767 )   $ 4,477  
Adjustments to reconcile net income (loss) to net cash provided by operating activities:        
Depreciation and amortization   13,894     7,253  
Change in fair value of contingent consideration   12,697     (3,222 )
Share-based compensation expense   5,357     110  
Payment of contingent earnout consideration in excess of purchase price accrual   (1,727 )    
Amortization of deferred financing costs   384     1,117  
Loss on extinguishment of debt       115  
Issuance and vesting of Management Incentive Units       663  
Participation unit compensation       150  
Changes in operating assets and liabilities, net of effect of acquisitions:        
Premiums, commissions and fees receivable, net   (12,717 )   (441 )
Prepaid expenses and other current assets   230     (921 )
Due from related parties   2     73  
Accounts payable, accrued expenses and other current liabilities   23,418     5,090  
Other liabilities       105  
Net cash provided by operating activities   30,771     14,569  
Cash flows from investing activities:        
Capital expenditures   (4,135 )   (1,465 )
Investment in business venture       (200 )
Cash consideration paid for asset acquisitions, net of cash received   (695 )   (671 )
Cash consideration paid for business combinations, net of cash received   (230,403 )   (99,486 )
Net cash used in investing activities   (235,233 )   (101,822 )
Cash flows from financing activities:        
Proceeds from issuance of Class A common stock, net of underwriting discounts   167,346      
Repurchase/redemption of LLC Units and Class B common stock   (32,610 )    
Payment of common stock offering costs   (798 )    
Payment of contingent and guaranteed earnout consideration   (1,192 )   (813 )
Proceeds from revolving line of credit   185,637     68,464  
Repayments of revolving line of credit   (125,000 )    
Proceeds from related party debt       49,845  
Payments on long-term debt       (204 )
Payments of debt issuance costs and debt extinguishment costs   (2,182 )   (15 )
Proceeds from repayment of stockholder/member notes receivable   169     160  
Repurchase of common units       (12,500 )
Distributions       (9,831 )
Other   19     1,662  
Net cash provided by financing activities   191,389     96,768  
Net increase (decrease) in cash and cash equivalents and restricted cash   (13,073 )   9,515  
Cash and cash equivalents and restricted cash at beginning of period   71,071     7,995  
Cash and cash equivalents and restricted cash at end of period   $ 57,998     $ 17,510  

NON-GAAP FINANCIAL MEASURES

Adjusted EBITDA, Adjusted EBITDA Margin, Organic Revenue, Organic Revenue Growth, Adjusted Net Income, Adjusted Diluted Earnings Per Share (“EPS”), Pro Forma Revenue, Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA Margin are not measures of financial performance under GAAP and should not be considered substitutes for GAAP measures, including commissions and fees (for Organic Revenue, Organic Revenue Growth and Pro Forma Revenue), net income (loss) (for Adjusted EBITDA, Adjusted EBITDA Margin, Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA Margin), net income (loss) attributable to BRP Group, Inc. (for Adjusted Net Income) or diluted earnings (loss) per share (for Adjusted Diluted EPS), which we consider to be the most directly comparable GAAP measures. These non-GAAP financial measures have limitations as analytical tools, and when assessing our operating performance, you should not consider these non-GAAP financial measures in isolation or as substitutes for commissions and fees, net income (loss), net income (loss) attributable to BRP Group, Inc. or other consolidated income statement data prepared in accordance with GAAP. Other companies in our industry may define or calculate these non-GAAP financial measures differently than we do, and accordingly these measures may not be comparable to similarly titled measures used by other companies.

Adjusted EBITDA eliminates the effects of financing, depreciation, amortization and change in fair value of contingent consideration. We define Adjusted EBITDA as net income (loss) before interest, taxes, depreciation, amortization, change in fair value of contingent consideration and certain items of income and expense, including share-based compensation expense, transaction-related expenses related to Partnerships including severance, and certain non-recurring costs, including those related to raising capital. We believe that Adjusted EBITDA is an appropriate measure of operating performance because it eliminates the impact of expenses that do not relate to business performance, and that the presentation of this measure enhances an investor’s understanding of our financial performance.

Adjusted EBITDA Margin is Adjusted EBITDA divided by commissions and fees. Adjusted EBITDA Margin is a key metric used by management and our board of directors to assess our financial performance. We believe that Adjusted EBITDA Margin is an appropriate measure of operating performance because it eliminates the impact of expenses that do not relate to business performance, and that the presentation of this measure enhances an investor’s understanding of our financial performance. We believe that Adjusted EBITDA Margin is helpful in measuring profitability of operations on a consolidated level.

Adjusted EBITDA and Adjusted EBITDA Margin have important limitations as analytical tools. For example, Adjusted EBITDA and Adjusted EBITDA Margin:

  • do not reflect any cash capital expenditure requirements for the assets being depreciated and amortized that may have to be replaced in the future;
  • do not reflect changes in, or cash requirements for, our working capital needs;
  • do not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of our ongoing operations;
  • do not reflect the interest expense or the cash requirements necessary to service interest or principal payments on our debt;
  • do not reflect share-based compensation expense and other non-cash charges; and
  • exclude certain tax payments that may represent a reduction in cash available to us.

We calculate Organic Revenue Growth based on commissions and fees for the relevant period by excluding the first twelve months of commissions and fees generated from new Partners. Organic Revenue Growth is the change in Organic Revenue period-to-period, with prior period results adjusted for Organic Revenues that were excluded in the prior period because the relevant Partners had not yet reached the twelve-month owned mark, but which have reached the twelve-month owned mark in the current period. For example, revenues from a Partner acquired on June 1, 2019 are excluded from Organic Revenue for 2019. However, after June 1, 2020, results from June 1, 2019 to December 31, 2019 for such Partners are compared to results from June 1, 2020 to December 31, 2020 for purposes of calculating Organic Revenue Growth in 2020. Organic Revenue Growth is a key metric used by management and our board of directors to assess our financial performance. We believe that Organic Revenue and Organic Revenue Growth are appropriate measures of operating performance as they allow investors to measure, analyze and compare growth in a meaningful and consistent manner.

Adjusted Net Income is presented for the purpose of calculating Adjusted Diluted EPS. We define Adjusted Net Income as net income (loss) attributable to BRP Group, Inc. adjusted for amortization, change in fair value of contingent consideration and certain items of income and expense, including share-based compensation expense, transaction-related expenses related to Partnerships including severance, and certain non-recurring costs that, in the opinion of management, significantly affect the period-over-period assessment of operating results, and the related tax effect of those adjustments.

Adjusted Diluted EPS measures our per share earnings excluding certain expenses as discussed above and assuming all shares of Class B common stock were exchanged for Class A common stock. Adjusted Diluted EPS is calculated as Adjusted Net Income divided by adjusted dilutive weighted-average shares outstanding. We believe Adjusted Diluted EPS is useful to investors because it enables them to better evaluate per share operating performance across reporting periods.

Pro Forma Revenue reflects GAAP revenue (commissions and fees), plus revenue from Partnerships in the unowned periods.

Pro Forma Adjusted EBITDA takes into account Adjusted EBITDA from Partnerships in the unowned periods and eliminates the effects of financing, depreciation and amortization. We define Pro Forma Adjusted EBITDA as pro forma net income (loss) before interest, taxes, depreciation, amortization, change in fair value of contingent consideration and certain items of income and expense, including share-based compensation expense, transaction-related expenses related to Partnerships including severance, and certain non-recurring costs, including those related to raising capital. We believe that Pro Forma Adjusted EBITDA is an appropriate measure of operating performance because it eliminates the impact of expenses that do not relate to business performance, and that the presentation of this measure enhances an investor’s understanding of our financial performance.

Pro Forma Adjusted EBITDA Margin is Pro Forma Adjusted EBITDA divided by Pro Forma Revenue. Pro Forma Adjusted EBITDA is a key metric used by management and our board of directors to assess our financial performance. We believe that Pro Forma Adjusted EBITDA is an appropriate measure of operating performance because it eliminates the impact of expenses that do not relate to business performance, and that the presentation of this measure enhances an investor’s understanding of our financial performance. We believe that Pro Forma Adjusted EBITDA Margin is helpful in measuring profitability of operations on a consolidated level.

Adjusted EBITDA and Adjusted EBITDA Margin

The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net income (loss), which we consider to be the most directly comparable GAAP financial measure to Adjusted EBITDA and Adjusted EBITDA Margin:

    For the Three Months

 Ended September 30,
  For the Nine Months

 Ended September 30,
    2020   2019   2020   2019
Commissions and fees   $ 65,843     $ 38,383     $ 171,270     $ 101,280  
                 
Net income (loss)   $ (7,615 )   $ (2,306 )   $ (10,767 )   $ 4,477  
Adjustments to net income (loss):                
Amortization expense   5,185     3,082     13,231     6,793  
Change in fair value of contingent consideration   6,455     535     12,697     (3,222 )
Share-based compensation   2,240     382     5,357     773  
Interest expense, net   922     3,785     2,554     8,998  
Depreciation expense   258     184     663     460  
Transaction-related Partnership expenses   2,904     500     6,772     1,535  
Severance related to Partnership activity   (324 )       89     300  
Capital related expenses       1,124     1,000     2,214  
Income tax provision           12      
Other   899     92     1,733     391  
Adjusted EBITDA (1)   $ 10,924     $ 7,378     $ 33,341     $ 22,719  
Adjusted EBITDA Margin   17 %   19 %   19   22 %

__________

(1)   Adjusted EBITDA for the nine months ended September 30, 2019 is higher than the sum of Adjusted EBITDA for the first three quarters of 2019 as disclosed in our earnings releases in 2020 as a result of rounding numbers in the prior periods.

Organic Revenue and Organic Revenue Growth

The following table reconciles Organic Revenue to commissions and fees, which we consider to be the most directly comparable GAAP financial measure to Organic Revenue:

    For the Three Months

 Ended September 30,
For the Nine Months

 Ended September 30,
(in thousands, except percentages)   2020   2019   2020   2019
Commissions and fees   $ 65,843     $ 38,383     $ 171,270     $ 101,280  
Partnership commissions and fees (1)   (19,637 )   (17,520 )   (54,569 )   (36,749 )
Organic Revenue   $ 46,206     $ 20,863     $ 116,701     $ 64,531  
Organic Revenue Growth (2)   $ 7,809     $ 2,297     $ 15,393     $ 5,479  
Organic Revenue Growth % (2)   20 %   12 %   15 %   9 %

__________

(1)   Includes the first twelve months of such commissions and fees generated from newly acquired Partners.
(2)   Organic Revenue for the three and nine months ended September 30, 2019 used to calculate Organic Revenue Growth for the three and nine months ended September 30, 2020 was $38.4 million and $101.3 million, respectively, which is adjusted to reflect revenues from Partnerships that reached the twelve-month owned mark during the three and nine months ended September 30, 2020.

Adjusted Net Income and Adjusted Diluted EPS

The following table reconciles Adjusted Net Income to net income (loss) attributable to BRP Group, Inc. and reconciles Adjusted Diluted EPS to diluted loss per share attributable to BRP Group, Inc. Class A common stock:

(in thousands, except per share data)   For the Three Months Ended September 30, 2020   For the Nine Months Ended September 30, 2020
Net loss attributable to BRP Group, Inc.   $ (3,268 )   $ (5,388 )
Net loss attributable to noncontrolling interests   (4,347 )   (5,379 )
Amortization expense   5,185     13,231  
Change in fair value of contingent consideration   6,455     12,697  
Share-based compensation   2,240     5,357  
Transaction-related Partnership expenses   2,904     6,772  
Capital related expenses       1,000  
Amortization of deferred financing costs   189     384  
Severance related to Partnership activity   (324 )   89  
Other   899     1,733  
Adjusted pre-tax income   9,933     30,496  
Adjusted income taxes (1)   983     3,019  
Adjusted Net Income   $ 8,950     $ 27,477  
         
Weighted-average shares of Class A common stock outstanding – diluted   33,098     24,371  
Dilutive effect of unvested restricted shares of Class A common stock   759     483  
Exchange of Class B shares (2)   45,288     44,767  
Adjusted dilutive weighted-average shares outstanding   79,145     69,621  
         
Adjusted Diluted EPS   $ 0.11     $ 0.39  
         
Diluted loss per share   $ (0.10 )   $ (0.22 )
Effect of exchange of Class B shares and net loss attributable to noncontrolling interests per share       0.07  
Other adjustments to net loss per share   0.22     0.58  
Adjusted income taxes per share   (0.01 )   (0.04 )
Adjusted Diluted EPS   $ 0.11     $ 0.39  

___________

(1)   Represents corporate income taxes at assumed effective tax rate of 9.9% applied to adjusted pre-tax income.
(2)   Assumes the full exchange of Class B shares for Class A common stock pursuant to the Amended LLC Agreement.

Pro Forma Revenue

The following table reconciles Pro Forma Revenue to commissions and fees, which we consider to be the most directly comparable GAAP financial measure to Pro Forma Revenue:

    For the Three Months

 Ended September 30,
For the Nine Months

 Ended September 30,
(in thousands)   2020   2019   2020   2019
Commissions and fees   $ 65,843     $ 38,383     $ 171,270     $ 101,280  
Revenue for Partnerships in the unowned period (1)   232     430     30,690     14,769  
Pro Forma Revenue   $ 66,075     $ 38,813     $ 201,960     $ 116,049  

___________

(1)   The adjustments for the three months ended September 30, 2020 reflect commissions and fees revenue for Fletcher Financial Group, Inc. and Medicare Insurance Advisors, Inc. as if the Company had acquired the Partners on January 1, 2020. The adjustments for the nine months ended September 30, 2020 reflect commissions and fees revenue for AgencyRM LLC, VibrantUSA Inc., Insurance Risk Partners, LLC, Southern Protective Group, LLC, Pendulum, LLC, Rosenthal Bros., Inc., Trinity Benefit Advisors, Inc./Russ Blakely & Associates, LLC, Fletcher Financial Group, Inc. and Medicare Insurance Advisors, Inc. as if the Company had acquired the Partners on January 1, 2020. The adjustments for the three months ended September 30, 2019 reflect commissions and fees revenue for Foundation Insurance of Florida, LLC and one asset acquisition for the unowned period as if the Company had acquired the Partners on January 1, 2019. The adjustments for the nine months ended September 30, 2019 reflect commissions and fees revenue for Lykes Insurance, Inc., Millennial Specialty Insurance LLC, Fiduciary Partners Retirement Group, Inc. and Foundation Insurance of Florida, LLC, as well as two asset acquisitions for the unowned period, as if the Company had acquired the Partners on January 1, 2019. This unaudited pro forma information should not be relied upon as being indicative of the historical results that would have been obtained if the acquisitions had occurred on that date, nor the results that may be obtained in the future.

Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA Margin

The following table reconciles Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA Margin to net income (loss), which we consider to be the most directly comparable GAAP financial measure to Pro Forma Adjusted EBITDA and Pro Forma Adjusted EBITDA Margin:

    For the Three Months

 Ended September 30,
For the Nine Months

 Ended September 30,
(in thousands)   2020   2019   2020   2019
Pro Forma Revenue   $ 66,075     $ 38,813     $ 201,960     $ 116,049  
                 
Net income (loss)   $ (7,615 )   $ (2,306 )   $ (10,767 )   $ 4,477  
Net income (loss) for Partnerships in the unowned period (1)   27     136     9,885     (472 )
Pro Forma Net Income (Loss)   (7,588 )   (2,170 )   (882 )   4,005  
Adjustments to pro forma net income (loss):                
Interest expense, net   922     3,785     3,997     13,011  
Amortization expense   5,206     3,082     16,135     8,652  
Change in fair value of contingent consideration   6,455     535     12,697     (3,222 )
Share-based compensation   2,240     382     5,357     773  
Transaction-related Partnership expenses   2,904     500     6,772     1,535  
Depreciation expense   258     184     663     460  
Severance related to Partnership activity   (324 )       89     300  
Capital related expenses       1,124     1,000     2,214  
Income tax provision           12      
Other   899     92     1,733     391  
Pro Forma Adjusted EBITDA (2)   $ 10,972     $ 7,514     $ 47,573     $ 28,119  
Pro Forma Adjusted EBITDA Margin   17   19 %   24 %   24 %

___________

(1)   The adjustments for the three months ended September 30, 2020 reflect net income (loss) for Fletcher Financial Group, Inc. and Medicare Insurance Advisors, Inc. as if the Company had acquired the Partners on January 1, 2020. The adjustments for the nine months ended September 30, 2020 reflect commissions and fees revenue for AgencyRM LLC, VibrantUSA Inc., Insurance Risk Partners, LLC, Southern Protective Group, LLC, Pendulum, LLC, Rosenthal Bros., Inc., Trinity Benefit Advisors, Inc./Russ Blakely & Associates, LLC, Fletcher Financial Group, Inc. and Medicare Insurance Advisors, Inc. as if the Company had acquired the Partners on January 1, 2020. The adjustments for the three months ended September 30, 2019 reflect commissions and fees revenue for Foundation Insurance of Florida, LLC and one asset acquisition for the unowned period as if the Company had acquired the Partners on January 1, 2019. The adjustments for the nine months ended September 30, 2019 reflect commissions and fees revenue for Lykes Insurance, Inc., Millennial Specialty Insurance LLC, Foundation Insurance of Florida, LLC and Fiduciary Partners Retirement Group, Inc., as well as two asset acquisitions for the unowned period, as if the Company had acquired the Partners on January 1, 2019. This unaudited pro forma information should not be relied upon as being indicative of the historical results that would have been obtained if the acquisitions had occurred on that date, nor the results that may be obtained in the future.
(2)   Pro Forma Adjusted EBITDA for the nine months ended September 30, 2019 is higher than the sum of Pro Forma Adjusted EBITDA for the first three quarters of 2019 as disclosed in our earnings releases in 2020 as a result of rounding numbers in the prior periods. 

COMMONLY USED DEFINED TERMS

The following terms have the following meanings throughout this press release unless the context indicates or requires otherwise:

Clients Our insureds
   
Colleagues Our employees
   
GAAP Accounting principles generally accepted in the United States of America
   
Partners Companies that we have acquired, or in the case of asset acquisitions, the producers
   
Partnerships Strategic acquisitions made by the Company

IMPORTANT NOV. 23 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Golar LNG Limited– GLNG

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Golar LNG Limited (NASDAQ: GLNG) from April 24, 2020 through September 24, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Golar LNG Limited investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) certain employees, including Hygo’s CEO, had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo’s valuation ahead of its IPO would be significantly impaired; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]